Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

Full text
Author(s):
Goswami, Dibakar [1, 2] ; Vitorino, Hector A. [1] ; Alta, Roxana Y. P. [1] ; Silvestre, Daniel M. [1] ; Nomura, Cassiana S. [1] ; Teresa Machini, M. [3] ; Esposito, Breno P. [1]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Dept Quim Fundamental, BR-05508000 Sao Paulo - Brazil
[2] Bhabha Atom Res Ctr, Div Bioorgan, Bombay 400085, Maharashtra - India
[3] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508000 Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: BIOMETALS; v. 28, n. 5, p. 869-877, OCT 2015.
Web of Science Citations: 4
Abstract

Deferasirox (DFX), an orally active and clinically approved iron chelator, is being used extensively for the treatment of iron overload. However, its water insolubility makes it cumbersome for practical use. In addition to this, the low efficacy of DFX to remove brain iron prompted us to synthesize and evaluate a DFX-TAT(47-57) peptide conjugate for its iron chelation properties and permeability across RBE4 cell line, an in vitro model of the blood-brain barrier. The water-soluble conjugate was able to remove labile iron from buffered solution as well as from iron overloaded sera, and the permeability of DFX-TAT(47-57) conjugate into RBE4 cells was not affected compared to parent deferasirox. The iron bound conjugate was also able to translocate through the cell membrane. (AU)

FAPESP's process: 11/18958-0 - Chelator-peptide conjugates permeable to the blood-brain barrier as protectors against iron-induced toxicity
Grantee:Dibakar Goswami
Support Opportunities: Scholarships in Brazil - Post-Doctoral